

Memory Care Monthly

Supporting Healthcare Professionals in Caring for the Aging

October 2006

Cancer-Related Cognitive Impairment (CRCI)

October is National Breast Cancer Awareness Month. In commemoration, this month we focus our attention on the link between cancer and cognitive impairment.

Cancer treatment has made great strides since the initial clinical trials of the National Cancer Institute were begun in the 1960s. Many fatal cancers in the 1960s are now routinely curable or have very good prognoses. As a consequence of the longer survival in a variety of cancers, new issues have arisen. One of those is cancer-related cognitive impairment (**CRCI**). The importance of CRCI is underscored by the fact that life expectancy due to cognitive impairment is the same as that due to cancer¹. CRCI is a common complaint. Detecting and diagnosing CRCI will allow use of treatment that can ameliorate cognitively related functional disability and may improve quality of life.



Published studies examining the occurrence of CRCI have identified the following:

Whole Brain Irradiation produces CRCI in a dose dependent fashion².

Low dose irradiation to the frontal or posterior brain areas of infants produces CRCI during their adulthood³.

Methotrexate, cytosine arabinoside and ifosfamide can cause acute encephalopathy, aseptic meningitis, plus delayed syndromes of cognitive impairment, hemiparesis, aphasia and progressive dementia. They are most likely to occur when these treatments are given in high doses, high frequency or co-administered with radiation therapy.

Primary CNS lymphoma patients surviving ≥ 4 years who are treated with methotrexate and radiation therapy develop leukoencephalopathy associated with impaired attention and memory⁴.

Opiates increase the likelihood of CRCI in early stage cancer patients and delirium in advanced stage cancer patients⁵.

Cancer survivors ≥ 65 years old and cancer patients who survive longer than 5 years are more than twice as likely to have CRCI or dementia⁶.

Nonmetastatic breast cancer patients, prior to receiving chemotherapy, show CRCI in verbal learning and memory⁷.

Breast cancer patients two years after adjuvant high-dose cyclophosphamide, thiotepa, or carboplatin chemotherapy or after conventional cyclophosphamide, methotrexate, or 5-fluorouracil chemotherapy have a higher risk of CRCI compared to breast cancer stage 1 patients. Whether CRCI lasts longer than two years in these patients is not settled⁸.

Long-term survivors of childhood acute lymphoblastic leukemia and solid tumors have a significantly increased prevalence of CRCI⁹.

Among **acute myelogenous leukemia and myelodysplastic syndrome patients prior to treatment**, higher IL-6 levels associate with poorer executive function, and higher IL-8 levels associate with better memory performance¹⁰.

Tuberous Sclerosis increases the risk of autism¹¹.

Neurofibromatosis type 1 greatly increases the risk of CRCI¹².

Among **long-term survivors of childhood brain tumors**, CRCI is more likely to occur with younger age at time of treatment, longer survival time, in females, and in the presence of hydrocephalus. CRCI is related to loss of white matter or failure to myelinate in the frontal lobe and cingulate gyrus^{13,14}.

The likelihood of CRCI is a function of both radiation dose and the volume of brain irradiated¹³. CRCI progresses faster during the first few years after radiation therapy and more gradually later on¹⁵.

Primary CNS Hodgkin's lymphoma patients who survive longer than 1 year virtually all develop cognitive impairment¹⁶.

Low grade gliomas of the brain produced CRCI that is exacerbated by high dose cranial irradiation and by anticonvulsants¹⁷.

Brain tumors in the frontal or temporal lobes impair executive function, attention and memory¹⁸.

Small cell lung cancer patients frequently have CRCI¹⁹.

Pancreatic cancer patients are more likely to develop Alzheimer's disease²⁰.

Familial adenomatous polyposis patients frequently have CRCI²¹.

Patients with **paraneoplastic syndromes** develop CRCI and other psychopathology²².

The mechanisms underlying CRCI include:

Slowing of nerve conduction velocity in the brain as measured by event related potentials during learning⁹.

Leukoencephalopathy in long-term survivors treated with methotrexate and radiation therapy or methotrexate and cytosine arabinoside. The leukoencephalopathy of methotrexate may be due to disturbed folate metabolism leading to decreased folate and S-adenosylmethionine levels plus increased homocysteine and adenosine levels^{23,24}.

Gliosis leading to cognitive impairment can occur in patients treated with cisplatin in a dose- and frequency-dependent manner²⁵. In culture and animal models, cisplatin induces apoptosis, which can be reduced by NMDA receptor modulating agonists, possibly memantine²⁶.

Chemotherapy delivered directly into the cerebrospinal fluid (i.e., by Ommaya reservoir) leads to clinically significant leukoencephalopathy in more than half of long-term treatment survivors and has a significant negative impact on quality of life²⁷.

Fludarabine and possibly other immunosuppressive chemotherapeutic agents increases risk for infection with the JC virus, which leads to progressive multifocal leukoencephalopathy²⁸. Fludarabine is used to treat low-grade lymphoproliferative diseases such as chronic lymphocytic leukemia and follicular lymphoma.

Published studies of the effects of treating CRCI:

1. Cancer patients treated with **recombinant human erythropoietin** (epoetin alfa) show a reduction in cognitive impairment, possibly related to reduction of hypoxia-induced neuronal damage from various therapeutic protocols.
2. Administration of low molecular weight sulfur-containing agents that increase cellular glutathione levels has been shown to reduce the in vitro toxicity of the alkylating agents, melphalan, carboplatin, and cisplatin. Of sodium thiosulfate, N-acetylcysteine, and glutathione ethyl ester, N-Acetylcysteine was the most effective protectant tested²⁹.

The issue of identifying and treating CRCI is in its infancy. However, some existing treatments may counteract underlying mechanisms of CRCI to improve outcomes. Without further knowledge, the use of such treatment needs to be done safely on a trial and error basis.

Reference List

1. Extermann M. Older patients, cognitive impairment, and cancer: an increasingly frequent triad. *J Natl Compr Canc Netw* 2005; 3:593-596.
2. Gregor A, Cull A, Traynor E, Stewart M, Lander F, Love S. Neuropsychometric evaluation of long-term survivors of adult brain tumours: relationship with tumour and treatment parameters. *Radiother Oncol* 1996; 41:55-59.
3. Hall P, Adami HO, Trichopoulos D et al. Effect of low doses of ionising radiation in infancy on cognitive function in adulthood: Swedish population based cohort study. *BMJ* 2004; 328:19.
4. Herrlinger U, Kuker W, Uhl M et al. NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report. *Ann Neurol* 2005; 57:843-847.
5. Lawlor PG. The panorama of opioid-related cognitive dysfunction in patients with cancer: a critical literature appraisal. *Cancer* 2002; 94:1836-1853.
6. Heflin JL, Meyerowitz BE, Hall P et al. Cancer as a risk factor for long-term cognitive deficits and dementia. *J Natl Cancer Inst* 2005; 97:854-856.
7. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. 'Chemobrain' in breast carcinoma?: a prologue. *Cancer* 2004; 101:466-475.
8. Schagen SB, Muller MJ, Boogerd W et al. Late effects of adjuvant chemotherapy on cognitive function: a follow-up study in breast cancer patients. *Ann Oncol* 2002; 13:1387-1397.
9. Lahteenmaki PM, Holopainen I, Krause CM, Helenius H, Salmi TT, Heikki LA. Cognitive functions of adolescent childhood cancer survivors assessed by event-related potentials. *Med Pediatr Oncol* 2001; 36:442-450.
10. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. *Cancer* 2005; 104:788-793.
11. Hunt A, Shepherd C. A prevalence study of autism in tuberous sclerosis. *J Autism Dev Disord* 1993; 23:323-339.
12. Hyman SL, Shores A, North KN. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. *Neurology* 2005; 65:1037-1044.
13. Mulhern RK, Merchant TE, Gajjar A, Reddick WE, Kun LE. Late neurocognitive sequelae in survivors of brain tumours in childhood. *Lancet Oncol* 2004; 5:399-408.
14. Mulhern RK, White HA, Glass JO et al. Attentional functioning and white matter integrity among survivors of malignant brain tumors of childhood. *J Int Neuropsychol Soc* 2004; 10:180-189.
15. Spiegler BJ, Bouffet E, Greenberg ML, Rutka JT, Mabbott DJ. Change in neurocognitive functioning after treatment with cranial radiation in childhood. *J Clin Oncol* 2004; 22:706-713.
16. O'Neill BP, Wang CH, O'Fallon JR et al. The consequences of treatment and disease in patients with primary CNS non-Hodgkin's lymphoma: cognitive function and performance status. North Central Cancer Treatment Group. *Neuro-oncol* 1999; 1:196-203.
17. Taphoorn MJ. Neurocognitive sequelae in the treatment of low-grade gliomas. *Semin Oncol* 2003; 30:45-48.
18. Tucha O, Smely C, Preier M, Lange KW. Cognitive deficits before treatment among patients with brain tumors. *Neurosurgery* 2000; 47:324-333.
19. Kanard A, Frytak S, Jatoi A. Cognitive dysfunction in patients with small-cell lung cancer: incidence, causes, and suggestions on management. *J Support Oncol* 2004; 2:127-132.
20. Burke WJ, McLaughlin JR, Chung HD et al. Occurrence of cancer in Alzheimer and elderly control patients: an epidemiologic necropsy study. *Alzheimer Dis Assoc Disord* 1994; 8:22-28.
21. Levitt AJ, Rodin G, Cohen Z, Berk T. Coping styles, psychopathology and intellectual performance in patients with familial adenomatous polyposis. *Gen Hosp Psychiatry* 1992; 14:61-68.
22. Gnatyshak AI, Boguta K. [Paraneoplastic psychopathologic syndromes]. *Vopr Onkol* 1990; 36:918-921.
23. Quinn CT, Griener JC, Bottiglieri T, Arning E, Winick NJ. Effects of intraventricular methotrexate on folate, adenosine, and homocysteine metabolism in cerebrospinal fluid. *J Pediatr Hematol Oncol* 2004; 26:386-388.
24. Fliessbach K, Helmstaedter C, Urbach H et al. Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. *Neurology* 2005; 64:1184-1188.
25. Steeghs N, de Jongh FE, Sillevis Smitt PA, van den Bent MJ. Cisplatin-induced encephalopathy and seizures. *Anticancer Drugs* 2003; 14:443-446.
26. Gozdz A, Habas A, Jaworski J et al. Role of N-methyl-D-aspartate receptors in the neuroprotective activation of extracellular signal-regulated kinase 1/2 by cisplatin. *J Biol Chem* 2003; 278:43663-43671.
27. Siegal T. Toxicity of treatment for neoplastic meningitis. *Curr Oncol Rep* 2003; 5:41-49.
28. Vidarsson B, Mosher DF, Salamat MS, Isaksson HJ, Onundarson PT. Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease. *Am J Hematol* 2002; 70:51-54.
29. Muldoon LL, Walker-Rosenfeld SL, Hale C, Purcell SE, Bennett LC, Neuwelt EA. Rescue from enhanced alkylator-induced cell death with low molecular weight sulfur-containing chemoprotectants. *J Pharmacol Exp Ther* 2001; 296:797-805.
30. Schütz KH, Heesen C. [Effects of exercise in chronically ill patients. Examples from oncology and neurology]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz* 2005; 48:906-913.

Potential agents that could improve function in CRCI:

1. Glutamatergic Modulation of Long-Term Potentiation
 - a. Memantine (Namenda)
 - b. Amantadine (Symmetrel)
2. Cholinesterase Inhibitors
 - a. Rivastigmine (Exelon)
 - b. Galantamine (Razadyne)
 - c. Donepezil (Aricept)
 - d. Huperzine alpha
3. ADHD Medications
 - a. Methylphenidate (Ritalin, Concerta, Focalin)
 - b. Dexedrine (Adderal)
 - c. Atomoxetine (Strattera)
4. Dopaminergic therapy
 - a. Dopamine precursors: Levodopa (Sinemet, Stalevo)
 - b. Dopamine agonists: Pramipexole (Mirapex)
 - c. Catechol O-Methyl Transferase inhibitors (COMTAN)
 - d. Monamine Oxidase Inhibitors: Selegeline (Eldepryl, Deprenyl)
5. Selective Serotonergic antidepressants
 - a. Paroxetine (Paxil)
 - b. Sertraline (Zoloft)
 - c. Escitalopram (Lexapro)
6. Selective Noradrenergic/Dopaminergic antidepressants
 - a. Duloxetine (Cymbalta)
 - b. Mirtazapine (Remeron)
 - c. Venlafaxine (Effexor)
 - d. Desipramine (Norpramin)
 - e. Bupropion (Wellbutrin)
7. Antihypoxia Treatment
 - a. recombinant human erythropoietin
8. Glutathione antioxidant therapy with alkylating chemotherapeutics
 - a. N-Acetylcysteine
 - b. R-alpha lipoic acid
9. Hypothalamic Nuclear Stimulation
 - a. Modafinil (Provigil)
10. Cognitive Therapy
 - a. Sudoku
 - b. Posit Science Program to improve executive dysfunction
11. Physical Exercise³⁰

Research Update

Cognitive Complaints in Older Adults May be Associated with Underlying Neurodegenerative changes

New research shows brain atrophy in older adults with cognitive complaints similar to that in subjects with amnesic types of mild cognitive impairment (aMCI). Saykin et al from Dartmouth Medical School have compared structural brain MRI scans of 40 euthymic individuals with cognitive complaints (CC) who had normal neuropsychological test performance with those of 40 patients with aMCI and 40 healthy controls (NL) using voxel-based morphometry and hippocampal volumes analysis. The CC and aMCI groups showed similar patterns of decreased grey matter, compared to the NL group, with differences evident in the medial temporal, frontotemporal, and other regions. The degree of grey matter loss was associated with extent of both memory complaints and performance deficits. This study suggests that cognitive complaints in older adults may be associated with underlying neurodegenerative changes.

Reference

Saykin AJ, et al. Older adults with cognitive complaints show brain atrophy similar to that of amnesic MCI. *Neurology*. 2006; 67 (September 1 of 2): 834-42.

Research Shows High Interest among Older Adults in Screening and Treatment for Mild Cognitive Impairment

A recent study conducted by Dale et al at the University of Chicago found strong interest among healthy adults aged 35+ in being tested and treated for mild cognitive impairment (MCI) (n=149).

This study was conducted at two university-based geriatric waiting rooms in Chicago, and subjects were asked 12 attitudinal questions toward MCI and Alzheimer's disease (AD). These questions included "If you began to notice problems with your memory, would you go see your doctor to see if you have MCI?," "Would you want your doctor to test your memory to see if you have MCI as part of the medical exam even if you had not noticed any memory loss?," and "Would you want to know as early as possible that you had AD?."

Ninety-nine percent of respondents would be willing to be tested for MCI if a family member suggested they had memory problems, 99% were willing to take a medication if it would cut the risk to conversion from MCI to AD in half, and 92% would take a medication to delay the conversion from MCI to AD by 1 year.

In conclusion, the authors raised a concern about such high interest across the population given the limited ability to treat and delay the progression of some memory disorders. However, with rapidly advancing research on MCI and a promising pipeline of new treatments, public acceptance of early detection and treatment is encouraging.

Reference

Dale W et al. High Interests in Screening and Treatment for Mild Cognitive Impairment in Older Adults: A Pilot Study. JAGS. 2006;54:1388-94.

**November
is
Alzheimer's
Awareness Month**

Look for an e-mail in your in-box in October with a suggestion of how you can use the opportunity to educate your patients about the importance of early detection and treatment of Alzheimer's Disease

Share Your Experience

How have your patients benefited from early detection of memory disorders?

How has your practice incorporated memory assessment services?

If you are available to share your experiences, please send an email to customerservice@mccare.com and let us know what is a good time to call you.

We are looking forward to hearing from you.



Medical Care Corporation
Simple and Accurate Memory Assessment
19782 MacArthur Blvd. #310, Irvine, CA 92612
ww.mccare.com • (888)565-5535